U.S. Stock News

In the first quarter of 2026, Host Hotels & Resorts reported revenue of US$1.65 billion and net income of US$494 million, with basic and diluted earnings per share from continuing operations of US$0.72, all higher than the same period a year earlier. The company paired this earnings strength with higher full‑year RevPAR guidance, new quarterly and special dividends, and continued share repurchases, indicating management’s confidence in its capital allocation plans. We’ll now examine how the...

In late April 2026, Phathom Pharmaceuticals reported that its first-quarter net loss narrowed to US$30.37 million from US$94.32 million a year earlier, while maintaining full-year 2026 net revenue guidance of US$320 million to US$345 million and expecting operating profitability, excluding stock-based compensation, to begin in the third quarter of 2026. The company also disclosed a change in how it classifies certain third-party costs starting January 1, 2026, which could make future margins...

In the first quarter of 2026, Teladoc Health reported sales of US$613.85 million versus US$629.37 million a year earlier, with net loss narrowing to US$63.84 million and loss per share improving to US$0.36 from US$0.53. Alongside this, the company issued cautious 2026 revenue guidance and highlighted ongoing pressure in its BetterHelp mental health unit despite some progress in Integrated Care and cost efficiencies. We’ll now examine how Teladoc’s wider-than-expected adjusted loss and...

Backblaze, Inc. recently reported first-quarter 2026 results, with sales rising to US$38.67 million and its net loss narrowing to US$6.15 million, while also issuing revenue guidance of US$39.8 million to US$40.2 million for the second quarter. The company also raised its full-year 2026 revenue outlook to a range of US$161.5 million to US$163.5 million, signaling growing confidence in its business trajectory. Next, we'll examine how Backblaze's improved quarterly loss and higher full-year...

ANI Pharmaceuticals (ANIP) FY 2025 earnings snapshot ANI Pharmaceuticals (ANIP) just wrapped up FY 2025 with Q4 revenue of US$247.1 million and basic EPS of US$1.23, capping a year in which trailing twelve month revenue reached US$883.4 million and basic EPS came in at US$3.50. Over recent quarters, revenue has moved from US$190.6 million in Q4 2024 to US$247.1 million in Q4 2025, while quarterly basic EPS shifted from a loss of US$0.55 to a profit of US$1.23, pointing to a very different...

If you are wondering whether Doximity's current share price reflects its underlying value, this article walks through what the numbers are actually saying about the stock. Doximity recently closed at US$26.03, with the stock showing a 6.5% return over the last 7 days and 15.7% over the last 30 days, while the year to date return stands at a 39.9% decline and the 1 year return at a 56.1% decline. These price moves sit against a backdrop of ongoing interest in digital tools for healthcare...

Agnico Eagle Mines (NYSE:AEM) has launched a new share repurchase program of up to $2b. The normal course issuer bid allows buybacks of up to 5% of shares outstanding through May 2027. The program follows record Q1 net income and strong operating performance, after Board and regulatory approvals. The new $2b buyback comes as Agnico Eagle Mines trades around $187.77 a share, after a 10.4% decline over the past month but a 65.5% gain over the past year. Over the past 3 years the stock has...

In early May 2026, Wintrust Financial Corporation filed an omnibus shelf registration covering debt securities, common and preferred stock, depositary shares, warrants, stock purchase contracts, and stock purchase units, giving it the option to issue these instruments over time. This broad shelf registration enhances Wintrust Financial’s flexibility to access capital markets quickly, which can influence how investors view its future funding and growth options. With this expanded financing...

Lantronix, Inc. recently filed for a US$30.00 million at-the-market follow-on common stock offering after reporting third-quarter 2026 results that showed higher quarterly sales and a smaller net loss year-on-year. At the same time, Lantronix unveiled its Open-Q 8550CS micro SOM and NDAA- and TAA-compliant Drone Reference Platform, aiming to accelerate AI-enabled drone development for defense and commercial OEMs. We’ll now examine how the new drone-focused Open-Q 8550CS and Drone Reference...

Euronet Worldwide (EEFT) stock is in focus after first quarter 2026 results showed sales of US$1,011.8 million, with net income of US$37.5 million and diluted EPS from continuing operations of US$0.83. See our latest analysis for Euronet Worldwide. The earnings release and recent buyback activity come after a mixed stretch for the stock, with a 30 day share price return of 8.05% but a 1 year total shareholder return decline of 33.34%, suggesting that shorter term momentum has picked up while...

Fluor's FY 2025 headline numbers Fluor (FLR) has just posted a mixed FY 2025 finish, with fourth quarter revenue of US$4.2b and a reported loss of US$1.6b, translating to basic EPS of US$9.86. The trailing twelve months show revenue of US$15.5b and a small net loss of US$51m, or basic EPS of US$0.31. The company has seen quarterly revenue move between US$3.4b and US$4.3b over the past six reported periods. EPS has swung from a gain of US$14.91 in Q2 2025 and US$10.58 in Q4 2024 to losses in...

In recent weeks, Omnicom Group Inc. reported first-quarter 2026 results, completed a US$1,992.59 million buyback of 24,709,660 shares, announced a US$0.80 quarterly dividend payable on July 9, 2026, and confirmed a Google Cloud collaboration via its Creo unit to add generative AI tools to influencer content vetting and editing. Omnicom also reshaped its leadership bench by appointing Christine Gambino as CEO of its Omni platform and shifting Omnicom Commerce oversight to Flywheel CEO Alex...

Starwood Property Trust (STWD) just wrapped up FY 2025 with fourth quarter revenue of $148.8 million and basic EPS of $0.26, setting the tone for how investors will read the full year. The company has seen quarterly revenue move from $91.5 million in Q4 2024 to a range of $125.7 million to $148.8 million through 2025, while basic EPS has moved between $0.19 and $0.38 over the same stretch. This gives you a clear view of how the top line and per share results have tracked into this latest...

Astrana Health (ASTH) has wrapped up FY 2025 with fourth quarter revenue of US$950.5 million and basic EPS of US$0.12, alongside trailing 12 month revenue of about US$3.2 billion and EPS of US$0.46. This gives investors a clear read on both the latest quarter and the full year run rate. Over recent periods the company has seen quarterly revenue move from US$478.7 million in Q3 2024 to US$665.2 million in Q4 2024 and then into the US$620.4 million to US$956.0 million range through FY 2025,...

Wondering if Sempra at around US$91.57 is offering fair value or if you are paying up for recent momentum? This article breaks down what the current price might really mean for you. The stock has seen mixed moves recently, with a 3.7% decline over the last week and a 7.0% decline over the last month, while still showing returns of 2.1% year to date, 24.5% over 1 year, 31.2% over 3 years and 55.7% over 5 years. Recent attention on Sempra has been driven by ongoing interest in utilities that...

Veracyte, Inc. reported first-quarter 2026 results with revenue rising to US$139.07 million and net income to US$28.71 million, significantly ahead of the prior year and analyst expectations, and raised its full-year 2026 revenue guidance to a range of US$582 million–US$592 million. Alongside this financial strength, Veracyte is reinforcing the clinical footprint of its Decipher portfolio, with more than 15 new bladder and prostate cancer studies being presented at the 2026 American...

Ascendis Pharma (NasdaqGS:ASND) has just posted its Q1 2026 numbers, with revenue of €246.6 million and basic EPS of €10.2, alongside trailing twelve month revenue of €865.8 million and basic EPS of €8.12. Over the past year, revenue has moved from €363.6 million in Q4 2024 to €865.8 million on a trailing basis, while basic EPS has shifted from a trailing loss of €6.53 to positive €8.12. This sets up a quarter where reported profitability and revenue scale give investors a clearer view of how...

If you are wondering whether Becton Dickinson stock is offering good value right now, a good starting point is to line up its recent share performance against what investors are paying for the business. The stock last closed at US$153.26, with returns of 2.8% over the past week, a 1.1% decline over 30 days, a 21.4% decline year to date, and an 18.8% gain over the past year, which gives a mixed picture of sentiment and risk. Recent news coverage around Becton Dickinson has focused on its role...

If you are wondering whether Rithm Capital at around US$9.79 is a bargain or a value trap, the starting point is understanding what the current price actually reflects. The stock has recent returns of 0.1% over 7 days, 3.1% over 30 days, a 10.8% decline year to date, a 4.7% decline over 1 year, 64.2% over 3 years and 59.1% over 5 years. This gives you a mixed picture of short term weakness against longer term gains. Recent headlines have focused on Rithm Capital's positioning within...

Trinity Industries, Inc. reported past first-quarter 2026 results with revenue of US$492.0 million and net income of US$24.2 million, while also lifting full-year 2026 EPS guidance to a range of US$2.20 to US$2.40 excluding non-core items. The combination of lower revenue but higher earnings per share points to improved profitability, which underpins management’s confidence in raising earnings expectations for the year. Next, we’ll examine how this upgraded EPS outlook and margin improvement...

Celsius Holdings (NasdaqCM:CELH) reported Q1 2026 results with record revenue and over 20% U.S. energy drink market share. The company highlighted progress integrating Alani Nu and Rockstar Energy, which management describes as billion-dollar brands. Results also flagged rising risks, including heavy reliance on PepsiCo distribution under amended agreements. Celsius disclosed an US$85 million liability tied to ongoing litigation. Celsius Holdings, the energy drink company behind the Celsius...

In early May 2026, Graco held an investor access event where it reaffirmed its through-cycle long-term growth algorithm and raised its expectations for acquisition-driven contributions. This update gives investors a clearer view of how Graco plans to use mergers and acquisitions as a more meaningful lever in its growth mix. Next, we’ll examine how Graco’s expanded M&A contribution targets may influence its existing investment narrative and future expectations. Outshine the giants: these 16...

Why TSS (TSSI) is in focus after Q1 2026 earnings and leadership moves TSS (TSSI) is drawing attention after reporting Q1 2026 results that showed lower revenue and net income year over year, alongside new senior hires focused on AI infrastructure and enterprise technology. For the quarter ended March 31, 2026, TSS reported revenue of US$55.35 million compared with US$98.96 million a year earlier, with net income of US$2.28 million versus US$2.98 million in the prior period. Basic and diluted...

Investors may be wondering if Indivior Pharmaceuticals at US$39.60 is still offering value after its strong run, or if most of the upside is already reflected in the price. The stock has returned 7.7% over the last week, 30.0% over the last month, 10.8% year to date and 260.7% over the last year. This naturally raises questions about how the risk reward trade off now looks. Recent news around Indivior Pharmaceuticals has focused on its position in the pharmaceuticals space and how the market...